While the pulmonary renin-angiotensin system (PRAS) has long been an area of study in lung injury and fibrosis, it was brought to the forefront when the COVID-19 pandemic highlighted the significance of bronchoalveolar epithelial expression of angiotensin-converting enzyme 2 (ACE2). This evidence concerns the gene ACE2 and fibrosis.